ALK and non-small cell lung carcinoma: In the case of nonsmall cell lung cancer (NSCLC) medication, the US Food and Drug Administration (FDA), thus far, approved some receptor tyrosine kinase inhibitors associated with multitargeted affinity, for instance, ErbB family inhibitor Afatinib, ALK/RET dual-blocker Alectinib, and ALK/MET/ROS1 multi-inhibitor Crizotinib [6,7].